BRBS

Blue Ridge is a small ($2.43B assets) Virginia commercial bank emerging from a rough patch. After a $51.8M loss in FY2023 and a $15.4M loss in FY2024 — the legacy of its fintech/BaaS troubles — it swung back to $10.7M net income in FY2025 (+169.6% YoY) with diluted EPS of $0.11. Crucially, the FY2025 10-K carries an UNQUALIFIED audit opinion from the PCAOB-registered firm AND an unqualified opinion on internal control over financial reporting effectiveness — a meaningful signal that the control and remediation issues that plagued the company have been addressed. Total assets shrank 11.1% and liabilities 12.5%, consistent with a deliberate shrink-to-strength deleveraging that has stabilized equity ($324M, only -1.2%). The single critical audit matter — the allowance for credit losses on collectively-evaluated loans — is standard for a bank and the reported ACL of $19.4M against $1.9B of gross loans (~1.0% coverage) looks adequately reserved via a DCF-primary methodology.

The valuation lens that matters here is price-to-book, not the reported P/E of 32.6 or the absurd P/S of 103.2 (the revenue tag is a stale FY2020 $3.18M figure — ignore both ratios; they are artifacts of bank accounting, not signal). Equity of $324M over 91.3M shares is ~$3.55/share of book value, so at $3.59 the stock trades at roughly 1.0x tangible book. For a bank earning a 3.3% return on equity, ~1x book is a full — arguably rich — price: healthy banks compounding 10%+ ROE earn a book premium, while a 3.3%-ROE bank normally deserves a discount to book. The market is therefore already paying up for a recovery that has only just begun.